RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Half of surveyed branded pharmaceutical companies had positive experiences with generics manufacturing partnerships. Only 14% had negative experiences, according to recent research by Cutting Edge Information.
Many companies work with generics manufacturers on counter-generic tactics, whether the strategy is employed through an authorized generic or the company’s own generics subsidiary. Many companies report positive experiences with these tactics — especially if the brand company chooses the correct partner, as one interviewed executive pointed out. Some other executives — even those who experience positive outcomes from these partnerships — report some disadvantages to partnerships with generics manufacturers.
The study, “Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion,” surveyed biopharmaceutical executives experiences working with generics manufacturers. Options range from very negative to very positive. Companies report a largely positive picture, with half of all companies rating their experiences as either “positive” or “very positive.” No company reports a “very negative” experience.
Surveyed companies show a stark decrease in partnership satisfaction as company size increases. Only Top 10 companies rate experiences as “negative,” whereas only small companies rate experiences as “very positive.” Top 50 companies remain largely neutral to partnerships with generics manufacturers, with only one surveyed company reporting a positive experience.
By far, generics licensing deals are initiated by the branded company facing loss of exclusivity. One pharmaceutical executive said that, when working with generics partnerships, the company involves “usually our financial department, our managing director, and marketing in those negotiations.” These negotiations, the executive explained, usually last a matter of months. “The idea is to try and introduce a generic product that we manufacture for them around 6 to 12 months prior to loss of exclusivity.
“Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion,” (http://www.cuttingedgeinfo.com/research/portfolio-management/counter-generics/) profiles more than 15 counter-generics strategies, team structures and staffing, and includes 39 case studies of companies’ approaches to combating generics.
Use this report to:
- Plan for and implement a diverse and robust set of strategies.
- Build a strong counter-generics task force early.
- Prepare for emerging biosimilar competition and changing approval pathways.
For more information about Counter-Generics and Biosimilars, contact Cassie Demeter at 919-403-6583.
